University Hospital Basel
Basel, 4031, Switzerland
NCT Number: NCT01616407
The purpose of this study is to assess and compare the effects of a single dose of 3,4-methylenedioxymethamphetamine (MDMA)and methylphenidate (MPH) on emotional and social cognition in healthy subjects. The investigators hypothesize that MDMA enhances affective perception for positive and impairs perception for negative emotional stimuli compared to placebo or MPH.
Looking for future studies?
Notify Me18 year–45 year
All sexes
Interventional
Early Phase 1
Basel, 4031, Switzerland
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
75 mg per os, single dose
Other names: - MDMA, - ecstasy
40 mg per os, single dose
Other names: - Ritalin, - Concerta
capsules identical to MDMA or methylphenidate but containing no active drug
Time frame: 7 hours
Time frame: 7 hours
Time frame: 7 hours
subjective effects are repetitively assessed by standardized questionnaires
Time frame: 7 hours
neuroendocrine parameters assessed: prolactin, cortisol, epinephrine, norepinephrine, oxytocin, pro-vasopressin, vasopressin, estrogene,and progesterone
Time frame: 7 hours
The plasma concentration of MDMA and MPH is repetitively assessed.
Time frame: assessed after study completion
Effects of genetic polymorphisms on the response to MDMA
University Hospital, Basel, Switzerland
Other
Effects of MDMA (Ecstasy) and Methylphenidate (Ritalin) on Social Cognition
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT04406675
Social Cognition
Angers, France
View Trial DetailsNCT05922956
Bipolar Disorder I and II, Facial Affect
Amiens, France
View Trial DetailsNCT06213194
Autism Spectrum Disorder, Autism or Autistic Traits
Istanbul, Basaksehir, Turkey (Türkiye)
View Trial DetailsNCT06164964
Social Cognition
View Trial Details